Chemical: Drug
medroxyprogesterone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for medroxyprogesterone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1544410 NC_000012.11:g.48239835C>T, NC_000012.12:g.47846052C>T, NG_008731.1:g.63980G>A, NM_000376.2:c.1024+283G>A, NM_001017535.1:c.1024+283G>A, NM_001017536.1:c.1174+283G>A, XM_006719587.2:c.1024+283G>A, XM_011538720.1:c.1024+283G>A, XR_944903.1:n.-763C>T, rs386536760, rs56495123, rs56911380
C > T
SNP
No VIP available CA VA
rs9340799 NC_000006.11:g.152163381A>G, NC_000006.12:g.151842246A>G, NG_008493.1:g.156751A>G, NM_000125.3:c.453-351A>G, NM_001122740.1:c.453-351A>G, NM_001122741.1:c.453-351A>G, NM_001122742.1:c.453-351A>G, NM_001291230.1:c.453-351A>G, NM_001291241.1:c.453-351A>G, XM_005266856.1:c.453-351A>G, XM_005266857.1:c.453-351A>G, XM_006715374.2:c.453-351A>G, XM_006715375.2:c.-67-351A>G, XM_011535543.1:c.453-351A>G, XM_011535544.1:c.453-351A>G, XM_011535545.1:c.453-351A>G, XM_011535546.1:c.453-351A>G, XM_011535547.1:c.453-351A>G, XM_011535548.1:c.-67-351A>G, rs17208058, rs59875577
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • CBP-1011
  • Hydroxymethylprogesterone
  • MAP
  • Medroprogesterone Acetate
  • Medrossiprogesterone [Dcit]
  • Medroxiprogesterona [INN-Spanish]
  • Medroxiprogesteronum
  • Medroxyprogesteron
  • Medroxyprogesteron acetate
  • Medroxyprogesteronum [INN-Latin]
Trade Names
  • Aragest
  • Aragest 5
  • Asconale
  • Clinofem
  • Clinovir
  • Colirest
  • DMPA
  • Depo-Clinovir
  • Depo-Prodasone
  • Depo-Progestin
  • Depo-Promone
  • Depot-Medroxyprogesterone acetate
  • Farlutal
  • Farlutin
  • G-Farlutal
  • Gestapuran
  • Hematrol
  • Hysron
  • Indivina
  • Lunelle
  • Lutopolar
  • Lutoral
  • MPA Gyn 5
  • Med-Pro
  • Meprate
  • Metigestrona
  • Nadigest
  • Nidaxin
  • Novo-Medrone
  • Oragest
  • Perlutex
  • Perlutex Leo
  • Prodasone
  • Progestalfa
  • Progevera
  • Provera
  • Proverone
  • Ralovera
  • Repromap
  • Repromix
  • Sirprogen
  • Sodelut G
  • Veramix
Brand Mixture Names
  • Lunelle (Medroxyprogesterone + Estradiol)

PharmGKB Accession Id

PA450344

Type(s):

Drug

Description

(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator.

Source: Drug Bank

Indication

Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

Source: Drug Bank

Pharmacology

Medroxyprogesterone is a synthetic progestin more potent than progesterone.

Source: Drug Bank

Food Interaction

Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

90%

Source: Drug Bank

Absorption

Rapidly absorbed from GI tract

Source: Drug Bank

Half-Life

50 days

Source: Drug Bank

Toxicity

Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.

Source: Drug Bank

Route of Elimination

Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H32O3

Source: Drug Bank

Isomeric SMILES

C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C

Source: Drug Bank

[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C

Source: Drug Bank

Canonical SMILES

C[C@H]1C[C@H]

Source: Drug Bank

Average Molecular Weight

344.4877

Source: Drug Bank

Monoisotopic Molecular Weight

344.23514489

Source: Drug Bank

SMILES

[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C

Source: Drug Bank

InChI String

InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ESR1 (source: Drug Bank )
PGR (source: Drug Bank )

Drug Interactions

Interaction Description
bosentan - medroxyprogesterone Decreases the effect of contraceptive (source: Drug Bank )
bosentan - medroxyprogesterone Decreases the effect of contraceptive (source: Drug Bank )
fosphenytoin - medroxyprogesterone The enzyme inducer, fosphenytoin, decreases the effect of the hormone, medroxyprogesterone. (source: Drug Bank )
griseofulvin - medroxyprogesterone The enzyme inducer decreases the effect of the hormones (source: Drug Bank )
griseofulvin - medroxyprogesterone The enzyme inducer, griseofulvin, decreases the effect of the hormone, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - acenocoumarol The agent increases the effect of anticoagulant (source: Drug Bank )
medroxyprogesterone - acenocoumarol Medroxyprogesterone may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank )
medroxyprogesterone - amobarbital The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - amobarbital The enzyme inducer, amobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - anisindione Medroxyprogesterone may increase the anticoagulant effect of anisindione. (source: Drug Bank )
medroxyprogesterone - aprobarbital The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - bosentan Bosentan decreases the effect of contraceptive (source: Drug Bank )
medroxyprogesterone - bosentan Bosentan decreases the effect of contraceptive (source: Drug Bank )
medroxyprogesterone - butabarbital The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - butalbital The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - butalbital The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - butethal The enzyme inducer, butethal, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - dicumarol The agent increases the effect of anticoagulant (source: Drug Bank )
medroxyprogesterone - dicumarol Medroxyprogesterone may increase the anticoagulant effect of dicumarol. (source: Drug Bank )
medroxyprogesterone - ethotoin The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - fosphenytoin The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - griseofulvin The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - griseofulvin The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - heptabarbital The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - hexobarbital The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - hexobarbital The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - mephenytoin The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - mephenytoin The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - methohexital The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - methylphenobarbital The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - methylphenobarbital The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - pentobarbital The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - pentobarbital The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - phenobarbital The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - phenobarbital The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - phenytoin The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - phenytoin The enzyme inducer, phenytoin, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - primidone The enzyme inducer decreases the effect of hormones (source: Drug Bank )
medroxyprogesterone - primidone The enzyme inducer, primidone, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - secobarbital The enzyme inducer, secobarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - talbutal The enzyme inducer, talbutal, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank )
medroxyprogesterone - warfarin The agent increases the effect of anticoagulant (source: Drug Bank )
medroxyprogesterone - warfarin Medroxyprogesterone may increase the anticoagulant effect of warfarin. (source: Drug Bank )
phenobarbital - medroxyprogesterone The enzyme inducer decreases the effect of hormones (source: Drug Bank )
phenobarbital - medroxyprogesterone The enzyme inducer, phenobarbital, decreases the effect of the hormone, medroxyprogesterone. (source: Drug Bank )
phenytoin - medroxyprogesterone The enzyme inducer decreases the effect of the hormones (source: Drug Bank )
phenytoin - medroxyprogesterone The enzyme inducer, phenytoin, decreases the effect of the hormone, medroxyprogesterone. (source: Drug Bank )
primidone - medroxyprogesterone The enzyme inducer decreases the effect of hormones (source: Drug Bank )
primidone - medroxyprogesterone The enzyme inducer, primidone, decreases the effect of the hormone, medroxyprogesterone. (source: Drug Bank )
thiopental - medroxyprogesterone Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. (source: Drug Bank )
thiopental - medroxyprogesterone Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. (source: Drug Bank )
warfarin - medroxyprogesterone Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed. (source: Drug Bank )

Publications related to medroxyprogesterone: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug metabolism and disposition: the biological fate of chemicals. 2008. Zhang Jiang-Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Human genetics. 1998. Deng H W, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0009-0064-06
DrugBank:
DB00603
ChEBI:
6715
KEGG Compound:
C07119
PubChem Compound:
10631
PubChem Substance:
46508895
9330
Drugs Product Database (DPD):
2247583
ChemSpider:
10185
Therapeutic Targets Database:
DAP001211
FDA Drug Label at DailyMed:
a586be28-96af-4fed-a13f-9b94fd4c7405

Clinical Trials

These are trials that mention medroxyprogesterone and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.